Blog
Blog
AI-driven Advancements in Life Sciences
The momentum behind AI-driven advancements in life sciences has never been stronger, and this trend was spotlighted in Everest Group’s new 2025 PEAK Matrix® report, “Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025.” Trinity Life Sciences is honored to be recognized as a Leader in this comprehensive assessment, a distinction rooted…

Filter posts by:
Blog
What Does “Good” Look Like in Customer Engagement?
First, what does “omnichannel” mean in life sciences? Omnichannel is a customer-centric strategy leveraging technology, data and analytics across functions to optimize cross-channel engagement. So, why is it so hard to achieve effective customer engagement impact? There are some companies...

Blog
IRA “Negotiations” Price Release: No Big Surprises, But Is the Industry Ready Today and for the Future?
Yesterday, CMS released the results of the first round of “negotiated” prices for the Inflation Reduction Act (IRA).1 The IRA is a historical landmark legislation for the pharmaceutical industry, and the results from these “negotiations” involving 10 of the top Medicare...

Blog
The Next Wave of Global AI Medical Devices: Innovation in Action
A recent bipartisan initiative by Senators Martin Heinrich, Mike Rounds, Marsha Blackburn and Todd Young urged the Centers for Medicare & Medicaid Services (CMS) to establish a formal payment pathway for algorithm-based health care services (ABHS). This move addresses the need...

Blog
Developing Effective Global Value Dossiers
Trinity Life Sciences recently worked with a large global pharma company to develop a new process for creating global value dossiers (GVDs) that better met the needs of regional affiliates. Matt O’Hara, who leads Trinity’s Evidence Strategy practice, shares insights into...

Blog
Rise with the Waves: UK – Now and Beyond – Four Policy Trends That May Shape Pharma’s Future
Executive Summary The global payer landscape is rapidly evolving and is expected to continuously impact manufacturers’ decisions about new launches, portfolio management, trial design and importantly, pricing and market access strategy. In the UK, several policy reforms have been introduced which...

Blog
Japan Pricing Policy Reform 2024
Executive Summary The Central Social Insurance Medical Council, the key Japanese reimbursement policy panel known as Chuikyo, introduced the 2024 drug pricing reform in April 2024. Some key features of the reform plan include: The reform outlines a suite of measures aimed at...
